Health & Fitness
Tue, March 13, 2012Mon, March 12, 2012Sat, March 10, 2012Fri, March 9, 2012Thu, March 8, 2012Wed, March 7, 2012Tue, March 6, 2012Mon, March 5, 2012Fri, March 2, 2012Thu, March 1, 2012Wed, February 29, 2012Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
Published in Health and Fitness on Wednesday, March 7th 2012 at 4:37 GMT by Market Wire
Synthetic Biologics to Present at ROTH Annual Growth Stock Conference -- ANN ARBOR, Mich., March 7, 2012 /PRNewswire/ --
Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
ANN ARBOR, Mich., March 7, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE Amex: [ SYN ]), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that Jeff Riley, the Company's Chief Executive Officer, will present at the ROTH Capital Partners 24th Annual Growth Stock Conference. The conference will be held March 11-14, 2012 at The Ritz Carlton in Dana Point, CA. Mr. Riley will present on Wednesday, March 14, 2012 at 2:30pm (PT).
A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the web at [ http://wsw.com/webcast/roth26/syn/ ]. After the presentation, a replay will be archived and accessible for 14 days at the same website.
ROTH Capital Partners, LLC
ROTH Capital Partners, LLC (ROTH) is a relationship-driven investment bank focused on identifying growth opportunities for corporate and institutional clients. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading and market-making services. Headquartered in Newport Beach, CA, ROTH is privately-held and owned by its employees, and maintains offices throughout the U.S., Hong Kong and a Shanghai Representative Office. For more information on ROTH, please visit [ www.roth.com ].
About Synthetic Biologics, Inc.
Synthetic Biologics is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Synthetic Biologics is developing, or has partnered the development of, product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis (ALS). For more information, please visit Synthetic Biologics' website at [ www.syntheticbiologics.com ].
SOURCE Synthetic Biologics, Inc.
[ Back to top ] RELATED LINKS
[ http://www.syntheticbiologics.com ]
